Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A updated results

• J.M. Piulats,
• E. Yu,
• G. Gravis,
• B. Laguerre,
• J. Arranz,
• S. Oudard,
• P. Fong,
• M. Kolinsky,
• M. Augustin,
• S. Feyerabend,
• A.. Kam,
• H. Gurney,
• A. Tafreshi,
• M. Retz,
• W. Berry,
• N. Mar,
• H. Wu,
• C. Schloss,
• C. Poehlein,
• J. De Bono

Affiliations

J.M. Piulats

E. Yu

G. Gravis

B. Laguerre

J. Arranz

S. Oudard

P. Fong

M. Kolinsky

M. Augustin

S. Feyerabend

A.. Kam

H. Gurney

A. Tafreshi

M. Retz

W. Berry

N. Mar

H. Wu

C. Schloss

C. Poehlein

J. De Bono